These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
757 related articles for article (PubMed ID: 33544720)
1. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. Fiscon G; Conte F; Farina L; Paci P PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720 [TBL] [Abstract][Full Text] [Related]
2. SAveRUNNER: an R-based tool for drug repurposing. Fiscon G; Paci P BMC Bioinformatics; 2021 Mar; 22(1):150. PubMed ID: 33757425 [TBL] [Abstract][Full Text] [Related]
3. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing. Das AB BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131 [TBL] [Abstract][Full Text] [Related]
4. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation. Gates LE; Hamed AA J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546 [TBL] [Abstract][Full Text] [Related]
5. Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19. Nisar H; Wajid B; Anwar F; Ahmad A; Javaid A; Attique SA; Nisar W; Saeed A; Shahid S; Sadaf S J Biomol Struct Dyn; 2024 Sep; 42(15):7972-7985. PubMed ID: 37534820 [TBL] [Abstract][Full Text] [Related]
6. LUNAR :Drug Screening for Novel Coronavirus Based on Representation Learning Graph Convolutional Network. Zhou D; Peng S; Wei DQ; Zhong W; Dou Y; Xie X IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1290-1298. PubMed ID: 34081583 [TBL] [Abstract][Full Text] [Related]
8. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis. Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981 [TBL] [Abstract][Full Text] [Related]
9. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. More SA; Patil AS; Sakle NS; Mokale SN Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743 [TBL] [Abstract][Full Text] [Related]
10. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. Prashantha CN; Gouthami K; Lavanya L; Bhavanam S; Jakhar A; Shakthiraju RG; Suraj V; Sahana KV; Sujana HS; Guruprasad NM; Ramachandra R J Mol Graph Model; 2021 Jan; 102():107769. PubMed ID: 33152616 [TBL] [Abstract][Full Text] [Related]
11. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
12. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696 [TBL] [Abstract][Full Text] [Related]
13. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Kröker A; Tirzīte M Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020 [TBL] [Abstract][Full Text] [Related]
14. Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics. Chakrabarty B; Das D; Bulusu G; Roy A IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1271-1280. PubMed ID: 33891554 [TBL] [Abstract][Full Text] [Related]
15. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827 [TBL] [Abstract][Full Text] [Related]
16. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032 [TBL] [Abstract][Full Text] [Related]
17. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19. Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089 [TBL] [Abstract][Full Text] [Related]
18. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497 [TBL] [Abstract][Full Text] [Related]
19. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking. Karki N; Verma N; Trozzi F; Tao P; Kraka E; Zoltowski B Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557253 [TBL] [Abstract][Full Text] [Related]
20. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19. Apaydın ÇB; Çınar G; Cihan-Üstündağ G Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]